Myeloma Trial, Recruiting NCT06099912 Sponsor: FengYan Jin Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06099912
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged 65 or older who either cannot receive a stem cell transplant or does not plan to have one right away
  • You have been diagnosed with multiple myeloma, confirmed by a bone marrow test showing at least 10% abnormal plasma cells, or a biopsy confirming a related tumor (plasmacytoma)
  • Your multiple myeloma can be measured through blood or urine tests showing certain protein levels above specific thresholds (confirm with trial site for exact values)
  • You have never received any treatment specifically targeting your multiple myeloma before
  • Your heart, liver, kidneys, and other organs are healthy enough to handle treatment
  • You (or your legal representative) are willing to sign a consent form and follow all the rules of the study

Who may not be able to join:

  • You currently have an active infection (such as a viral, fungal, or bacterial infection) that requires medication to treat it
  • You have serious heart or liver problems — for example, severe heart failure or significantly elevated liver enzymes — unless these are caused by multiple myeloma itself
  • You have had a previous blood cancer or solid tumor that was treated with radiation or chemotherapy within the last 5 years
  • You currently have another blood cancer or solid tumor that requires radiation or chemotherapy treatment
  • You are unwilling or unable to sign the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
FengYan Jin
Registry
ClinicalTrials.gov
Start date
8 September 2021
Est. completion
8 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall response rate (at least PR) on induction therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov